Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05019885 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

StatusCompleted
PhasePhase 2
Started2022-08-26
View on ClinicalTrials.gov ↗
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.

Amendment history 3 changes detected by DataLookout

2026-09-12
notable
Trial completed
2026-09-12
minor
Final enrollment: 12 participants (planned 8)
2026-09-12
minor
Primary completion confirmed: June 2026 (last estimated March 2026)
Trial Details
NCT Number NCT05019885
Lead Sponsor Madeline Fields
Conditions Drug Resistant Epilepsy, Medically Refractory Epilepsy, Refractory Epilepsy
Enrollment 12 participants
Start Date 2022-08-26
Primary Completion 2026-06-08 (estimated)
Study Completion 2026-06-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-11